Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis
Year: 2019
Type: article
Study design: Clinical Trial
Abstract: AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. RESULTS: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. CONCLUSION: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.
Source: Crohn s & Colitis 360
Authors: Elisa K Boden, James B Canavan, Christopher J Moran, Katelyn McCann, William A Dunn, Francis A Farraye, Ashwin N Ananthakrishnan, Vijay Yajnik, Roopali Gandhi, Deanna D Nguyen, Atul K Bhan, Howard L Weiner, Joshua R Korzenik, Scott B Snapper
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,378
OpenAlex ID: W2962276684